Published Journals

Science Translational Medicine: Volume 17 | Issue 788 | 5 Mar 2025

Broadly neutralizing antibodies targeting pandemic GII.4 variants or seven GII genotypes of human norovirus

Park et al.

Norovirus is a leading cause of gastroenteritis, and while most people recover quickly, young children, older adults, and immunocompromised individuals face a higher risk of severe disease. One of the biggest challenges in developing a vaccine is the virus’s extensive genetic diversity.

This study analyzed immune responses from recipients of an oral adenoviral-vectored norovirus vaccine and identified antibodies capable of neutralizing across different viral strains. A key antibody, VX22, targeted a highly conserved region of the viral capsid protein, revealing a structural site that could enable broad protection.

By demonstrating that a vaccine can elicit broadly neutralizing antibodies, this work provides a critical proof of concept and highlights a promising target for next-generation norovirus vaccine design.

For more information, see Bite-Sized Science